Fig. 6.
Fig. 6. Effect of the anti-α4 integrin MoAb HP2/1 (A) or the anti–VCAM-1 MoAb 5F10 (B) on TNFα-induced 111In-eosinophil accumulation in rat skin. (A) Animals were injected with a control MoAb MOPC-21 (3.5 mg/kg, IV▪) or MoAb HP2/1 (3.5 mg/kg, IV; □) 10 minutes before the intradermal administration of TNFα (10−12 or 10−11 mol/site). (B) Animals were injected with a control MoAb MOPC-21 (2 mg/kg, IV; ▪) or MoAb 5F10 (2 mg/kg, IV; □) 10 minutes before the intradermal administration of TNFα (10−12 or 10−11 mol/site). Using a 4-hour test period, the results are presented as mean ± SEM for n = 5 to 8 pairs of rats. Asterisks indicate a significant difference from MOPC-21–treated rats (*P < .05).

Effect of the anti-α4 integrin MoAb HP2/1 (A) or the anti–VCAM-1 MoAb 5F10 (B) on TNFα-induced 111In-eosinophil accumulation in rat skin. (A) Animals were injected with a control MoAb MOPC-21 (3.5 mg/kg, IV▪) or MoAb HP2/1 (3.5 mg/kg, IV; □) 10 minutes before the intradermal administration of TNFα (10−12 or 10−11 mol/site). (B) Animals were injected with a control MoAb MOPC-21 (2 mg/kg, IV; ▪) or MoAb 5F10 (2 mg/kg, IV; □) 10 minutes before the intradermal administration of TNFα (10−12 or 10−11 mol/site). Using a 4-hour test period, the results are presented as mean ± SEM for n = 5 to 8 pairs of rats. Asterisks indicate a significant difference from MOPC-21–treated rats (*P < .05).

Close Modal

or Create an Account

Close Modal
Close Modal